This public procurement contract involves the supply of pharmaceutical products for parenteral administration containing the active ingredient risankizumab (ATC L04AC18). These products are intended for the treatment of patients in approved indications according to the Summary of Product Characteris
Contract awarded. Originally published 1 years ago.
This public procurement contract involves the regular supply of medicinal products for parenteral administration containing the active substance tigecycline (ATC group J01AA12). These products are intended for the treatment of patients in approved indications according to the Summary of Product Char
This public procurement contract involves the ongoing supply of medical devices, specifically diagnostic strips for blood glucose testing. Suppliers are invited to provide these essential health products to support diabetes management. The total value of the contract is €5,250,000, and it is publish
This public procurement contract involves the repeated supply of specialized medical materials in accordance with the applicable medical device legislation. The focus is on balloon dilatation catheters that release sirolimus, which are essential for treating patients at the buyer's facilities. Suppl
This public procurement contract involves the repeated supply of specialized medical materials (SMM) in accordance with the current Medical Devices Act. The focus is on short-term catheter-based mechanical heart support systems necessary for treating patients at the buyer's facilities. The expected
Supply non-clinical consumables including forms, labels, and packaging for pathology and primary care services.
Procurement of RSV immunisation vaccine products for adult populations, scheduled for 2028.
Procurement for meningococcal ACWY vaccine supply in 2027 from qualified manufacturers or distributors.
Procurement opportunity for MMR vaccine supply with anticipated delivery timeline of 2027.
